Analysis of data from the DOMINO-AD Trial indicates that the drug Donepezil may be effective in avoiding care home admissions in more advanced cases of Alzheimer’s Disease. Discontinuation of donepezil appears to be associated with an increased risk of nursing home admissions in community-living patients with moderate-to-severe Alzheimer’s Disease during the first 12 months following drug cessation.
Withdrawing dementia drug doubles risk of nursing home placement. London: Medical Research Council (MRC), October 26th 2015.
Triggle, N. (2015). Dementia drug ‘keeps patients out of nursing homes’. London: BBC Health News, October 27th 2015.
This relates to:
Full Text Link (Note: This article requires a suitable Athens password, a journal subscription or payment for access).
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO-AD) trial: secondary and post-hoc analyses. The Lancet Neurology. [Epub ahead of print].
Background information on the DOMINO-AD trial:
Jones, R. Sheehan, B. [and] Phillips, P. [et al] (2009). DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer’s disease – a multicentre RCT. Trials, July 24th 2009, 10, 57. (Click here to view the PubMed abstract).